Hepatocellular carcinoma
Conditions
Interventions
Triple therapy group(Hepatic artery infusion chemotherapy combined with angiogenesis inhibitors and PD-1/PD-L1 blockers):NA
HAIC group (Hepatic artery infusion chemotherapy alone.):NA
TI group (Angiogenesis inhibitors and PD-1/PD-L1 blockers):NA
Sponsors
Sun Yat-sen University Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1: Hepatocellular carcinoma was diagnosed with typical imaging features of liver cancer and elevated AFP or pathologyHepatocellular carcinoma was diagnosed with typical imaging features of liver cancer and elevated AFP or pathology 2: Diagnosed with BCLC B/C based on baseline hematological parameters and contrast-enhanced CT or MR 3: At least one intra-hepatic focus to be evaluated 4: Without history of cell-immune therapu such as CAR-T, CIK and so on. 5: At least one accessible contrast-enhanced CT or MR data after the treatment, and the target foci can be assessed based on RECIST 1.1 6: ECOG PS 0-2 7: Tumor invasion into the main portal vein, and/or portal vein tumor thrombus involving the main portal vein or the contralateral first grade branch (Vp4), and/or bile duct invasion and/or tumor diameter >10cm 1. Triple therapy group: (1) Receive at least one immunocheckpoint inhibitor treatment; (2) Receive at least one dose of anti angiogenic drugs; (3) Accept HAIC at least once (3) The interval between the use of two drugs is within one month; (4) Except for HAIC, the last local treatment interval should be more than 3 months after combined treatment; (5) During the imaging evaluation period before and after treatment, the anti angiogenic drugs and immune checkpoint inhibitors remained consistent. 2. Targeted immunotherapy group: (1) Receive at least one immunocheckpoint inhibitor treatment; (2) Receive at least one dose of anti angiogenic drugs; (3) The interval between the use of two drugs is within one month; (4) The last local treatment interval should be more than 3 months after combined treatment; (5) During the imaging evaluation period before and after treatment, the anti angiogenic drugs and immune checkpoint inhibitors remained consistent. 3. HAIC treatment group: (1) Receive at least one HAIC treatment; (2) During the period of receiving HAIC (defined as one month before the start of the first HAIC and one month after the end of the last HAIC), no other systemic or local treatment was received.
Exclusion criteria
Exclusion criteria: 1: Loss of clinical information or image data 2: Severe damage of heart, brain, lung, kidney and other important organs 3: Loss of follow-up data 4: History of other malignant tumors in the past 3 years or at the same time
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival;Objective response rate;Disease-control rate; | — |
Countries
China
Contacts
Public ContactMengxuan Zuo
Sun Yat-sen University Cancer Center
Outcome results
None listed